This is an open-label Phase Ib dose-escalation study to assess MTD, safety, tolerability, and PK of PTC596 when combined with standard paclitaxel and carboplatin for women with stage III or IV epithelial ovarian, primary peritoneal or fallopian tube cancer receiving neoadjuvant chemotherapy. For all cohorts, PTC596 will be given in combination with paclitaxel and carboplatin.